In the selection of first-line chemotherapy regimens, ENKTL is insensitive to anthracycline-containing treatment due to the high expression of P-glycoprotein in the tumor cells, resulting in multidrug resistance (18). This evidence concerns the gene ABCB1 and neoplasm.